U24HD101059
Cooperative Agreement
Overview
Grant Description
Heal Initiative: Antenatal Opioid Exposure Longitudinal Study Consortium - Project Summary/Abstract
While the health, social, and economic impacts of opioid addiction on adults are well known, the impact of maternal opioid use on the fetus exposed in utero is less well understood.
The Outcomes of Babies with Opioid Exposure (OBOE) Study is an ongoing longitudinal cohort study to prospectively examine the medical, neurodevelopmental, and behavioral outcomes of children who were exposed to opioids in utero as compared with unexposed controls.
The objectives of the OBOE Study are to, over the first 2 years of life, (1) determine the impact of antenatal opioid exposure on brain structure and connectivity; (2) define medical, developmental, and behavioral outcomes in infants exposed to opioids; and (3) explore whether and how the home environment, maternal mental health, and parenting modify trajectories of brain connectivity and neurodevelopment.
In response to RFA-HD-24-015, RTI will continue to achieve the following specific aims as the Data Coordinating Center (DCC) for this renewal grant:
(1) Collaborate with study investigators in developing OBOE protocols and budgets;
(2) Support OBOE protocol design, training, and implementation;
(3) Provide data management for the consortium, including programming data management systems and preparing reports for the SSMB, SC, OBOE subcommittees, clinical centers, and NICHD/NIH;
(4) Provide the neuroimaging expertise for the consortium to help ensure standardization of neuroimaging data acquisition, monitor image acquisition, promote sharing among sites, review and assess images, and provide subject matter expertise for study result analyses;
(5) Conduct statistical analyses of study data for interim monitoring, final results, and secondary data analyses, and collaborate with study investigators to publish results of OBOE studies in a timely and accurate manner;
(6) Manage capitation funds, disbursing payments to clinical centers based on enrolled patients and other study milestone triggers, specified in the study protocols and budgets; and
(7) Provide the logistical support necessary to run an effective and productive consortium.
The DCC and four OBOE clinical centers have a long history of successful collaboration on completed and ongoing neonatal follow-up studies, including MRI studies and those focused on neonatal opioid withdrawal syndrome.
RTI’s approach as the DCC has many innovations such as (1) using an RTI-developed avatar-based consenter video app to assist with the informed consent process;
(2) Combining RTI’s extensive data science and statistical expertise with the cutting-edge neuroimaging innovations of Children’s National Medical Center, we will complete one of the first studies on brain structure and connectivity in opioid-exposed infants;
(3) Integrating analysis of both MRI findings and comprehensive neurodevelopmental assessments;
(4) Analyzing serial MRI assessments to examine longitudinal trajectories through age 2; and
(5) Advancing emerging research on social determinants of health and their role in child development.
While the health, social, and economic impacts of opioid addiction on adults are well known, the impact of maternal opioid use on the fetus exposed in utero is less well understood.
The Outcomes of Babies with Opioid Exposure (OBOE) Study is an ongoing longitudinal cohort study to prospectively examine the medical, neurodevelopmental, and behavioral outcomes of children who were exposed to opioids in utero as compared with unexposed controls.
The objectives of the OBOE Study are to, over the first 2 years of life, (1) determine the impact of antenatal opioid exposure on brain structure and connectivity; (2) define medical, developmental, and behavioral outcomes in infants exposed to opioids; and (3) explore whether and how the home environment, maternal mental health, and parenting modify trajectories of brain connectivity and neurodevelopment.
In response to RFA-HD-24-015, RTI will continue to achieve the following specific aims as the Data Coordinating Center (DCC) for this renewal grant:
(1) Collaborate with study investigators in developing OBOE protocols and budgets;
(2) Support OBOE protocol design, training, and implementation;
(3) Provide data management for the consortium, including programming data management systems and preparing reports for the SSMB, SC, OBOE subcommittees, clinical centers, and NICHD/NIH;
(4) Provide the neuroimaging expertise for the consortium to help ensure standardization of neuroimaging data acquisition, monitor image acquisition, promote sharing among sites, review and assess images, and provide subject matter expertise for study result analyses;
(5) Conduct statistical analyses of study data for interim monitoring, final results, and secondary data analyses, and collaborate with study investigators to publish results of OBOE studies in a timely and accurate manner;
(6) Manage capitation funds, disbursing payments to clinical centers based on enrolled patients and other study milestone triggers, specified in the study protocols and budgets; and
(7) Provide the logistical support necessary to run an effective and productive consortium.
The DCC and four OBOE clinical centers have a long history of successful collaboration on completed and ongoing neonatal follow-up studies, including MRI studies and those focused on neonatal opioid withdrawal syndrome.
RTI’s approach as the DCC has many innovations such as (1) using an RTI-developed avatar-based consenter video app to assist with the informed consent process;
(2) Combining RTI’s extensive data science and statistical expertise with the cutting-edge neuroimaging innovations of Children’s National Medical Center, we will complete one of the first studies on brain structure and connectivity in opioid-exposed infants;
(3) Integrating analysis of both MRI findings and comprehensive neurodevelopmental assessments;
(4) Analyzing serial MRI assessments to examine longitudinal trajectories through age 2; and
(5) Advancing emerging research on social determinants of health and their role in child development.
Awardee
Funding Goals
THE EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENTS MISSION IS TO LEAD RESEARCH AND TRAINING TO UNDERSTAND HUMAN DEVELOPMENT, IMPROVE REPRODUCTIVE HEALTH, ENHANCE THE LIVES OF CHILDREN AND ADOLESCENTS, AND OPTIMIZE ABILITIES FOR ALL.
Grant Program (CFDA)
Funding Agency
Place of Performance
North Carolina
United States
Geographic Scope
State-Wide
Analysis Notes
Amendment Since initial award the total obligations have increased 67% from $1,144,969 to $1,909,404.
Research Triangle Institute was awarded
OBOE Study: Antenatal Opioid Exposure Impact on Infant Brain Development
Cooperative Agreement U24HD101059
worth $1,909,404
from National Institute on Drug Abuse in September 2019 with work to be completed primarily in North Carolina United States.
The grant
has a duration of 7 years 9 months and
was awarded through assistance program 93.279 Drug Abuse and Addiction Research Programs.
The Cooperative Agreement was awarded through grant opportunity HEAL Initiative: Limited Competition: Data Coordinating Center for Completion of the Outcomes of Babies with Opioid Exposure (OBOE) Study (U24 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 4/6/26
Period of Performance
9/20/19
Start Date
6/30/27
End Date
Funding Split
$1.9M
Federal Obligation
$0.0
Non-Federal Obligation
$1.9M
Total Obligated
Activity Timeline
Transaction History
Modifications to U24HD101059
Additional Detail
Award ID FAIN
U24HD101059
SAI Number
U24HD101059-503636948
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NT00 NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development
Funding Office
75N600 NIH National Insitute on Drug Abuse
Awardee UEI
JJHCMK4NT5N3
Awardee CAGE
3A730
Performance District
NC-90
Senators
Thom Tillis
Ted Budd
Ted Budd
Modified: 4/6/26